ChimericMed retweeted
18/ 🚩There are limited open clin trial sites in🇺🇸 states w/ the highest % of Black residents
🚩2/4 🇺🇸 states where >30% of population is Black ppl had 🚫no CAR-T or bispecific clinical trial openings
34% of the 🇺🇸 states had 🚫no CAR-T or bispecific clinical trial openings
#mmsm
ChimericMed retweeted
Friends - Exciting update from @yesrxmichigan ! We received our non-profit status and are eager to serve #Michiganders who are having difficulty affording their meds. Consider helping us by donating here! yesrx.org #cancer #oncology #financialtoxicity
ChimericMed retweeted
AMWA-MAC is proud to announce that Julianna Merten (@ChimericMed ) will speak on critical thinking at our 2023 Annual Conference!
Register today at
lnkd.in/eietNukt
View the conference schedule at
amwa-midatlantic.org/events/…
#AMWAMAC2023
ChimericMed retweeted
In patients who have had a median of 6 prior lines of therapy, the response rate with cilta-cel is 98%.
Stringent complete responses in 83%. So you can see why the myeloma field is optimistic.
ChimericMed retweeted
Cilta-cel CAR T cell therapy was just approved by FDA for multiple myeloma. Deep, sustained clinical responses: durable effect. Great for patients! #mmsm @IMFmyeloma @theMMRF @myelomacrowd @SylvesterCancer @JanssenUS biopharmadive.com/news/johns…
ChimericMed retweeted
19/END 🆓#CME bit.ly/34gr1uf
🔗Credit 👉 bit.ly/3H1XJhb
⏱️ #ICYMI Multiple Myeloma #MedTweetorial 🧵
w/ @jmikhaelmd, me, & @BonumCe
⏪ Current state of #MultipleMyeloma
⏪ Improved outcomes for pts
⏪ #HealthDisparities
nitter.cf/i/events/1486877284015…
ChimericMed retweeted
1/📣 #Hematology #OncTwitter HCPs
🧐Curious about how #BCMA therapies work?
🧩How they differ?
🆙1st @SurbhiSidanaMD
✅#mmsm #MedTweetorial 🧵
🆓#CME 🔗 bit.ly/34gr1uf
Supported by edu grants from @janssenUS @pfizer
Provided by @BonumCe
📊 What's your specialty?
50%Hematologist
7%Oncologist
19%IM Phys or Fellow/Trainee
24%APP, RN, PharmD, Other
42 votes • Final results ChimericMed retweeted
1/ 📣 #hemonc #OncTwitter HCPs
❔Do u 🤔:
🧩State of #MultipleMyeloma
🧩 Evolution & 🔮 tx
🆕 #MMSM #MedTweetorial 🧵 w/
👩🏫@SurbhiSidanaMD on deck
🆓#CME 🔗bit.ly/3G0dNia
Supported by edu grants from @janssenUS @pfizer
Provided by @BonumCe
📊 What's ur specialty?
84%Hematologist
0%Oncologist
16%IM Phys or Fellow/Trainee
0%APP, RN, PharmD, Other
19 votes • Final results ChimericMed retweeted
Accepting mediocrity in leadership in mid levels because you want people who are nice and compliant to orders from top means you end up with mediocrity in leadership in high levels in course of time.
#leadershipmatters
ChimericMed retweeted
Amazing, Breyanzi was Third CAR-T to be approved in 3L DLBCL but first to report + top-line interim data in 2L DLBCL (POD12) vs ASCT. #TcellRx #lymsm news.bms.com/news/corporate-…
ChimericMed retweeted
‼️ #ASCO21 abstracts are now available! Discover the latest cutting-edge clinical trials and scientific research that will be presented during the meeting ➡️ fal.cn/3fv1b
ChimericMed retweeted
Sadly I completely believe this finding. I am frequently reminded by the experiences of my female colleagues how much easier I have it online 😞 😡 #HeForShe
Mixed feelings sharing our study out in @JAMANetworkOpen today that shows the benefits of social media are more pronounced for men compared to #WomenInMedicine
jamanetwork.com/journals/jam…
ChimericMed retweeted
🆘Hems & Oncs - we need your help in IDing edu needs & practice gaps to design future @SoMeCME activities.
@DrCCutler @sghmd @ChimericMed 🙏4 your help!
1/ Polling🧵
Which method do you most frequently use to screen for dev. of VOD/SOS in stem cell transplant recipients?
100%👀 Monitor wt, bilirubin
0%Weekly doppler ultrasound
0%👀 biomarkers (eg, Ang-2)
42 votes • Final results ChimericMed retweeted
Join the Pharmacy SIG for a webinar Monday, May 4, from 12-1 p.m. CDT. SIG leaders will review the impact of COVID-19 and recommendations related to administrative workflows & drug therapies, and lead an open discussion to answer all of your questions! ow.ly/Wv2q50zpQow